Evidence map›Paper›PMID 27991921›Full record

ArticleOncogene2017

ROCK2/ras

S F Masre, N Rath, M F Olson, D A Greenhalgh

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. The effects of miRNA-1180 on suppression of pancreatic cancer.American journal of translational research · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

S F MasreSection of Dermatology and Molecular Carcinogenesis, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, Glasgow University, Glasgow, UK.
N RathMolecular Cell Biology Laboratory, Cancer Research UK, Beatson Institute for Cancer Research, Garscube Estate, Glasgow, UK.ORCID 0000-0002-2342-6843
M F OlsonMolecular Cell Biology Laboratory, Cancer Research UK, Beatson Institute for Cancer Research, Garscube Estate, Glasgow, UK.
D A GreenhalghSection of Dermatology and Molecular Carcinogenesis, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, Glasgow University, Glasgow, UK.
Cancer Research UK Scotland Institute · GBUniversity of Glasgow · GB

Funding

Cancer Research UK 18276
6 · The paper itself

Abstract

To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-activated ROCK2 (K14.ROCK

Indexed as

AnimalsCarcinogenesisCarcinoma, Squamous CellCell DifferentiationCell Transformation, NeoplasticCrosses, GeneticGene Expression Regulation, NeoplasticHumansKeratinocytesMiceNF-kappa Bp21-Activated KinasesPapillomaProto-Oncogene Proteins p21(ras)rho-Associated KinasesSkin NeoplasmsafimoxifeneHras protein, mouseNF-kappa Bp21-Activated KinasesPak1 protein, mouseProto-Oncogene Proteins p21(ras)rho-Associated KinasesRock2 protein, mouseTamoxifenTumor Suppressor Protein p53

Identifiers

PMID27991921
OpenAlexW2564783979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.